Roche to buy Spark Therapeutics
Roche Holding has entered a definitive merger agreement with Spark Therapeutics, as the Swiss drugmaker seeks to expand its ability to treat rare diseases through gene therapies, as well as build its hemophilia portfolio.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Gene Therapy | Genetics | Haemophilia | Hemophilia | Mergers and Aquisitions | Pharmaceuticals | Rare Diseases | Switzerland Health